Literature DB >> 12445494

Effect of giving up cigarette smoking and restarting in patients with clinically manifested atherosclerosis.

F Chehne1, A Oguogho, G Lupattelli, B Palumbo, H Sinzinger.   

Abstract

Cigarette smoking, a key risk factor for the development of vascular disease, is associated with an increased 8-epi-prostaglandin (PG) F(2alpha). Elevated 8-epi-PGF(2alpha) has been found in vascular tissue, blood and urine as well. We examined the influence of quitting cigarette smoking in 71 patients (38 males, 33 females; aged 32-67 a) with clinically manifested atherosclerosis and various risk factors. In addition, in eight patients with hypercholesterolemia without clinical manifestation of atherosclerosis quitting smoking was monitored as well. Twenty-six of the patients with manifested atherosclerosis and five with hypercholesterolemia restarted and the isoprostanes in plasma, serum and urine were monitored in these patients as well. Quitting cigarette smoking induces an immediate decline becoming significant after 1 or 2 weeks. Restarting smoking results in an increase in 8-epi-PGF(2alpha) reaching prevalues within almost 1 week. These findings indicate that the in vivo oxidation injury associated with cigarette smoking quickly decreases after quitting but increases soon after restarting immediately.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445494     DOI: 10.1054/plef.2002.0438

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  9 in total

1.  Rapid quantitative analysis of 8-iso-prostaglandin-F(2alpha) using liquid chromatography-tandem mass spectrometry and comparison with an enzyme immunoassay method.

Authors:  Jeffrey H Dahl; Richard B van Breemen
Journal:  Anal Biochem       Date:  2010-05-25       Impact factor: 3.365

Review 2.  F2-isoprostanes as an indicator and risk factor for coronary heart disease.

Authors:  Sean S Davies; L Jackson Roberts
Journal:  Free Radic Biol Med       Date:  2010-11-30       Impact factor: 7.376

Review 3.  The role of smoking cessation in the prevention of coronary artery disease.

Authors:  Andrew L Pipe; Sophia Papadakis; Robert D Reid
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

4.  Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection.

Authors:  Theresa Winhusen; Daniel J Feaster; Rui Duan; Jennifer L Brown; Eric S Daar; Raul Mandler; Lisa R Metsch
Journal:  AIDS Behav       Date:  2018-06

5.  Quantitation of mercapturic acid conjugates of 4-hydroxy-2-nonenal and 4-oxo-2-nonenal metabolites in a smoking cessation study.

Authors:  Heather C Kuiper; Brandi L Langsdorf; Cristobal L Miranda; Jacqueline Joss; Carole Jubert; John E Mata; Jan F Stevens
Journal:  Free Radic Biol Med       Date:  2009-10-09       Impact factor: 7.376

6.  In vitro and clinical studies examining the expression of osteopontin in cigarette smoke-exposed endothelial cells and cigarette smokers.

Authors:  Emma Bishop; Eugenia H Theophilus; Ian M Fearon
Journal:  BMC Cardiovasc Disord       Date:  2012-09-17       Impact factor: 2.298

7.  Influence of smoking on levels of urinary 8-iso Prostaglandin F2α.

Authors:  Angela van der Plas; Sandrine Pouly; Guillaume de La Bourdonnaye; Gizelle Baker; Frank Lüdicke
Journal:  Toxicol Rep       Date:  2018-11-20

8.  Effects of cessation of cigarette smoking on eicosanoid biomarkers of inflammation and oxidative damage.

Authors:  Joseph P McElroy; Steven G Carmella; Alisa K Heskin; Mei Kuen Tang; Sharon E Murphy; Sarah A Reisinger; Joni A Jensen; Dorothy K Hatsukami; Stephen S Hecht; Peter G Shields
Journal:  PLoS One       Date:  2019-06-28       Impact factor: 3.240

9.  Statistical analysis plan for "A randomised, controlled study to evaluate the effects of switching from cigarette smoking to using a tobacco heating product on health effect indicators in healthy subjects".

Authors:  Oscar M Camacho; Andrew Hedge; Frazer Lowe; Nik Newland; Nathan Gale; Mike McEwan; Christopher Proctor
Journal:  Contemp Clin Trials Commun       Date:  2020-01-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.